Home › NDC Lookup › RxCUI directory › RxCUI 2723106

Cyclobenzaprine hydrochloride 2.8 MG Sublingual Tablet — RxCUI 2723106

RxNorm drug concept · Semantic clinical drug
RxCUI 2723106 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2723106
Official nameCyclobenzaprine hydrochloride 2.8 MG Sublingual Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascyclobenzaprine hydrochloride 2.8 MG (equivalent to cyclobenzaprine 2.47 MG) Sublingual Tablet
FDA products mapped1
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cyclobenzaprine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's a muscle relaxant prescribed to help ease muscle spasms, pain, and stiffness from acute musculoskeletal injuries — like a back strain or a pulled muscle. It's meant to be used...
  • What is cyclobenzaprine actually used for?
  • Yes, drowsiness is one of the most common side effects — it's real and can be significant. You should not drive, operate heavy machinery, or do anything that requires sharp focus u...
  • Will this make me really drowsy? Can I drive?
📖 Read our full Cyclobenzaprine guide →

🕸️ Concept Web — How Cyclobenzaprine hydrochloride 2.8 MG Sublingual... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cyclobenzaprine hydrochloride 2.8 MG Sublingual Tablet RxCUI 2723106

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Cyclobenzaprine 21949
    • Cyclobenzaprine hydrochloride 52101
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tonmya 2723107
  3. Dose forms 17

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cyclobenzaprine Sublingual Tablet 2723103
    • Cyclobenzaprine hydrochloride Sublingual Tablet 2723105
    • Cyclobenzaprine Oral Product 1156628
    • Cyclobenzaprine Pill 1156629
    • Cyclobenzaprine Sublingual Product 2723102
    • Cyclobenzaprine hydrochloride Oral Product 2660158
    • Cyclobenzaprine hydrochloride Pill 2661873
    • Cyclobenzaprine hydrochloride Sublingual Product 2723104
    • +9 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 23 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cyclobenzaprine hydrochloride 2.8 MG SCDC · 2723101
  • Cyclobenzaprine Sublingual Tablet SCDF · 2723103
  • Cyclobenzaprine hydrochloride Sublingual Tablet SCDFP · 2723105
  • Cyclobenzaprine Oral Product SCDG · 1156628
  • Cyclobenzaprine Pill SCDG · 1156629
  • Cyclobenzaprine Sublingual Product SCDG · 2723102
  • Cyclobenzaprine hydrochloride Oral Product SCDGP · 2660158
  • Cyclobenzaprine hydrochloride Pill SCDGP · 2661873
  • Cyclobenzaprine hydrochloride Sublingual Product SCDGP · 2723104

Brand-Name Concepts

  • Cyclobenzaprine hydrochloride 2.8 MG Sublingual Tablet [Tonmya] SBD · 2723114
  • Cyclobenzaprine hydrochloride 2.8 MG [Tonmya] SBDC · 2723108
  • Cyclobenzaprine Sublingual Tablet [Tonmya] SBDF · 2723112
  • Cyclobenzaprine hydrochloride Sublingual Tablet [Tonmya] SBDFP · 2723113
  • Tonmya Oral Product SBDG · 2723109
  • Tonmya Pill SBDG · 2723110
  • Tonmya Sublingual Product SBDG · 2723111
  • Tonmya BN · 2723107

📦 FDA Products & Package NDCs

1 product · 4 package NDCs
4 package NDCs map to RxCUI 2723106 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70792-0102-14 14 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-14) TONMYA Tonix Medicines, Inc. 2025-09-15
70792-0102-30 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-30) TONMYA Tonix Medicines, Inc. 2025-10-23
70792-0102-60 60 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-60) TONMYA Tonix Medicines, Inc. 2025-09-15
70792-0102-90 90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-90) TONMYA Tonix Medicines, Inc. 2025-09-15
Observed labelers: Tonix Medicines, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$29.5770
Range $29.5770–$29.5770 · middle 50% $29.5770–$29.5770 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.